254 related articles for article (PubMed ID: 36906109)
21. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
22. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
23. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
24. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
[TBL] [Abstract][Full Text] [Related]
26. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
[TBL] [Abstract][Full Text] [Related]
27. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
28. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
29. Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
Mahmoudi S; Bernatz S; Althoff FC; Koch V; Grünewald LD; Scholtz JE; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
Eur J Radiol; 2022 Nov; 156():110556. PubMed ID: 36270195
[TBL] [Abstract][Full Text] [Related]
30. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
31. Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma.
Huizing L; Chen L; Roeth AA; Heij LR; Flinders B; Bouwense SAW; Balluff B; Neumann UP; Heeren RMA; Olde Damink SWM; Vreeken RJ; Schaap FG
Cell Oncol (Dordr); 2023 Jun; 46(3):629-642. PubMed ID: 36630049
[TBL] [Abstract][Full Text] [Related]
32. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
Özdemir BH
Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
[TBL] [Abstract][Full Text] [Related]
33. A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Xu RC; Wang F; Sun JL; Abuduwaili W; Zhang GC; Liu ZY; Liu TT; Dong L; Shen XZ; Zhu JM
J Transl Med; 2022 Dec; 20(1):579. PubMed ID: 36494846
[TBL] [Abstract][Full Text] [Related]
34. Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Mahmoudi S; Bernatz S; Ackermann J; Koch V; Dos Santos DP; Grünewald LD; Yel I; Martin SS; Scholtz JE; Stehle A; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
Clin Oncol (R Coll Radiol); 2023 May; 35(5):e312-e318. PubMed ID: 36804153
[TBL] [Abstract][Full Text] [Related]
35. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
[TBL] [Abstract][Full Text] [Related]
36. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
37. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA; Taddei T; Jain D; Zhang X
Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
[TBL] [Abstract][Full Text] [Related]
38. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases.
Wang Q; Xu Y; Wang SM; Hu AY; Pan YC; Zhang SH
Ann Diagn Pathol; 2021 Dec; 55():151828. PubMed ID: 34571341
[TBL] [Abstract][Full Text] [Related]
39. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
[TBL] [Abstract][Full Text] [Related]
40. Impact of socio-economic environment on incidence of primary liver cancer in France between 2006 and 2016.
Comoz B; Ollivier-Hourmand I; Bouvier AM; Nousbaum JB; Nguyen TTN; Launoy G; Bouvier V; Bryere J
Liver Int; 2024 Feb; 44(2):446-453. PubMed ID: 38010978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
